BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Fyodor Biotechnologies, Inc. Awarded a Fyodor Biotechnologies, Inc. National Science Foundation Grant


6/9/2011 9:39:12 AM

SBIR Grant Baltimore, MD – June 8, 2011 — Fyodor Biotechnologies, a Baltimore-based diagnostic and biopharmaceutical company, announced today that the National Science Foundation has awarded the company a Small Business Innovation Research (SBIR) Phase I grant. With the $150,000 funding, Fyodor plans to further progress the development of its innovative Urine Malaria Test (UMT) technology.

“We are pleased to receive this award from the National Science Foundation from among what we can be sure was a highly competitive list of leading-edge project proposals,” said Eddy Agbo, DVM, PhD, Chairman & CEO of Fyodor Biotechnologies. “We will use the funds to broaden the utilization of Fyodor’s malaria diagnostic which uses urine instead of blood, and thus can be performed without the need for trained persons or other materials, resources often in short supply in areas of the world where diagnosis within 24 hours is critical.”

Fyodor intends to demonstrate proof of principle of its next generation UMT for the simultaneous diagnosis of Plasmodium falciparum and P. vivax in one test. P. falciparum accounts for about 95 percent of clinical malaria in Africa, but only about 60 percent of clinical cases in Asia, South America, Western Pacific and the Mediterranean, where it often occurs as mixed infections with P. vivax, which accounts for 40 percent of cases. Such differential diagnosis is critical for both determining appropriate treatment and conducting epidemiological studies.

Fyodor’s flagship UMT product, which is currently undergoing validation testing, is used for the diagnosis of malaria caused by P. falciparum in persons with fever. Unlike currently available malaria diagnostics, it uses urine rather than blood, enabling point-of-care diagnosis even in remote areas where laboratory diagnosis is limited or non-existent. The UMT has the potential to facilitate current global efforts towards home-based diagnosis of malaria within 24 hours in all cases of fever.

About Malaria

Half of the world's population is at risk for malaria, and an estimated 225 million cases lead to nearly 800,000 deaths annually. The majority of deaths from malaria are in children under the age of five. Annually, about 18 million U.S. travelers visit malaria-endemic countries.

About Fyodor Biotechnologies, Inc.

Founded in 2008, Fyodor is focused on the research, development and manufacture of innovative diagnostic and biopharmaceutical products, first targeted to large emerging “frontier” markets in Africa. Fyodor’s efforts are also intended to galvanize biotechnology-based socio-economic development locally in sub-Saharan Africa, enhancing the region’s competitiveness in both the regional and global biotech marketplace, revolutionizing healthcare in the region. (www.fyodorbio.com)

National Science Foundation

The National Science Foundation (NSF) is an independent federal agency that supports fundamental research and education across all fields of science and engineering. In fiscal year (FY) 2010, its budget is about $6.9 billion. NSF funds reach all 50 states through grants to nearly 2,000 universities and institutions. Each year, NSF receives over 45,000 competitive requests for funding, and makes over 11,500 new funding awards. NSF also awards over $400 million in professional and service contracts yearly.

Contact:

Anne M. Derrick

VP, Business Development and Operations

Fyodor Biotechnologies, Inc. anne.derrick@fyodorbio.com

443-552-0437



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES